Reasons for HMA discontinuation in patients with MDS. (A) Azacitidine. (B) Decitabine. Each histogram bar represents total number of patients in that treatment cycle (that is 28-day treatment period). The color-coded sections in each histogram bar represents the distribution by proportion of patients who were still on treatment and those who discontinued HMA either because of death or end of study period or for reasons other than death or end of study period. Reason is classified as death if patient died within 3 months after the last HMA date. Reason is classified as end of study period if it is not classified as death and the last HMA date is within 3 months before the end of study period (31 December 2014).